Analysis10k / Blog
EN한국어ES
Company Snapshot · ABBV

AbbVie (ABBV): What This Company Actually Does

The short answer

AbbVie makes immunology and aesthetics injectables like Skyrizi, Rinvoq, and Botox that patients take repeatedly for years once they start, collecting a recurring payment split between insurers, Medicare, and patients every time a prescription is refilled.

Share price
$283.54
Market cap
~$501.2B
FY2025 revenue
$61.16B
FY2025 free cash flow
$17.82B

How AbbVie makes money

AbbVie develops immunology and aesthetics injectables—drugs like Skyrizi, Rinvoq, and Botox—that patients take repeatedly for years once they start, then collects payment every month a prescription is refilled. It manufactures the drugs itself and sells through a small number of wholesalers who reach hospitals and pharmacies.

R&D
Drug candidates
→
ABBVIE
In-house manufacturing
Immunology, aesthetics, neuroscience
→
3 major wholesalers
84% of receivables
concentrated here
→
Hospitals/pharmacies → patients
Repeat prescriptions
for chronic conditions

Simplified. The actual bill is split three ways—insurers, government (Medicare), and patient copays. Source: 10-K FY2025, p.82.

Where the revenue comes from

Revenue by therapeutic area — FY2025 (worldwide)

Immunology (Skyrizi, Rinvoq, Humira)
49.7%
Neuroscience (Botox Therapeutic, Vraylar, Ubrelvy)
17.6%
Oncology (Imbruvica, Venclexta)
10.9%
Other key products (Mavyret, Creon)
10.4%
Aesthetics (Botox Cosmetic, Juvederm)
7.9%
Eye care
3.4%

AbbVie runs as a single global segment with no formal business-unit breakout. Source: 10-K FY2025, p.40.

Reading the geography 76.2% of revenue is U.S.-based, with the remaining 23.8% concentrated in Germany, Japan, and Canada — markets with strong government price controls, limiting how much international growth can offset U.S. pricing pressure.

Source: 10-K FY2025, p.98 (Note 16).

Customers and competitors

AbbVie sells through a small number of U.S. wholesalers who account for essentially all domestic distribution—three wholesalers represent 84% of receivables, though their identities aren't disclosed.

  • Johnson & Johnson — competes directly with Skyrizi in psoriasis and ulcerative colitis via Stelara and Tremfya.
  • Eli Lilly — competes with Rinvoq and Skyrizi in autoimmune disease prescriptions via Taltz and Omvoh.
  • Merz and Ipsen — challenge Botox in both therapeutic and cosmetic markets with Xeomin and Dysport, respectively.

Source: 10-K FY2025, p.82.

The metric that matters most in this sector

AbbVie's largest product, Humira, hit a patent cliff in 2023 when U.S. biosimilars entered the market. Whether follow-on drugs Skyrizi and Rinvoq have actually replaced that lost revenue is the single clearest read on whether this company survived its biggest risk.

Humira vs. Skyrizi+Rinvoq combined revenue

YearHumiraSkyrizi + RinvoqTotal immunology
2021$20.69B$4.59B$25.28B
2022$21.24B$7.69B$28.92B
2023$14.40B$11.73B$26.14B
2024$8.99B$17.69B$26.68B
2025$4.54B$25.87B$30.41B

Source: 10-K FY2025, p.40; 10-K FY2022, p.42 (2021–2022 figures).

Worth noting Skyrizi and Rinvoq combined overtook Humira's peak revenue starting in 2024, and total immunology revenue hit a record in 2025 — one of the few clean examples of a company actually replacing a patent-cliff product. Both successor drugs still carry their own expiration dates, though: U.S. composition-of-matter patents run to 2033, with Rinvoq's extended to 2037 via settlement.

Source: 10-K FY2025, p.14.

Leadership and ownership

CEO Robert A. Michael took over in 2024 and added the board chair role in July 2025. He isn't the founder; he joined Abbott in 1993 and served as AbbVie's CFO from 2018 to 2022 before becoming CEO — a finance-background executive rather than an operations one. Officers and directors together hold under 1% of shares; the largest holders are passive index funds Vanguard (10.2%) and BlackRock (8.5%).

Source: 10-K FY2025, p.30; DEF 14A 2026, p.29.

Capital returns

AbbVie raised its quarterly dividend from $1.64 to $1.73 per share starting with the February 2026 payment ($6.92 annualized). Buybacks have shrunk for three straight years—$1.97B in 2023, $1.71B in 2024, and just $0.98B in 2025—while diluted weighted-average shares outstanding actually rose slightly over the same period, from 1.769B to 1.773B, as new shares issued for employee stock compensation offset the repurchases. In other words, the buyback program isn't currently defending against share dilution.

Source: 10-K FY2025, p.30, 52, 55.

How this company could fail

Failure scenario If Skyrizi and Rinvoq—the drugs that replaced Humira—lose patent protection between 2033 and 2037 with no comparable successor ready, AbbVie repeats the same revenue cliff it experienced in 2023.
  • Direct U.S. government price-setting (IRA) — under the Inflation Reduction Act, the government now directly negotiates Medicare prices for a growing list of AbbVie drugs: Imbruvica (starting 2026), Vraylar and Linzess (2027), and Botox (2028) — meaning even patent-protected drugs can face government-mandated price cuts.
  • The patent cliff repeats — Skyrizi and Rinvoq, now nearly half of total revenue, face U.S. composition-of-matter patent expiration in 2033 (2037 for Rinvoq). The concerns that hit Humira will resurface as those dates approach.
  • Concentration in a few wholesalers and pharmacy benefit managers — 84% of U.S. receivables run through three wholesalers, and PBMs control formulary placement. AbbVie has little negotiating leverage if terms turn unfavorable.

Source: 10-K FY2025, p.15–16 (IRA), p.14 (patents), p.82 (wholesaler concentration).

Five-year financials

Revenue: 2021 56,197, 2022 58,054, 2023 54,318, 2024 56,334, 2025 61,160. Free cash flow: 2021 21,990, 2022 24,248, 2023 22,062, 2024 17,832, 2025 17,81656,19721,990202158,05424,248202254,31822,062202356,33417,832202461,16017,8162025
RevenueFree cash flowSame figures as the table below.
$ millions unless noted
20212022202320242025
Revenue56,19758,05454,31856,33461,160
YoY growth—+3.3%-6.4%+3.7%+8.6%
Operating income17,92418,11712,7579,13715,075
Free cash flow21,99024,24822,06217,83217,816
Total debt76,68463,27159,38567,14467,496
Worth watching Operating income swung sharply in 2023–2024, but that wasn't a sign of underlying business trouble—it mostly reflects non-cash impairment charges and acquired-IPR&D expense from acquired drug assets (a $4.48B intangible-asset impairment in 2024 alone). Free cash flow stayed relatively stable at $178–242B throughout, a more reliable read on real earnings power. Debt, which had been falling from the 2021 Allergan-acquisition peak, ticked back up in 2024 on the ImmunoGen and Cerevel acquisitions.

Sources: 10-K FY2025, p.51 (income), p.55 (cash flow), p.53 (balance sheet); 10-K FY2022, p.49, 51 (2021–2022 figures). FCF = operating cash flow − capex.

What we still don't know

  • The exact identities and contract terms of the three U.S. wholesalers handling 84% of receivables aren't disclosed in the filing.
  • Whether the 2023–2024 earnings volatility reflects only acquisition-accounting effects or some underlying business slowdown can't be fully separated without reviewing each acquisition's amortization schedule individually.
  • The success probability of AbbVie's late-stage pipeline meant to fill the 2033–2037 patent gap isn't addressed by this filing alone and requires checking recent earnings calls and pipeline updates.
Built from AbbVie's 10-K filings for fiscal years 2021–2025, its 10-Q filings, and its 2026 DEF 14A, plus a web search for the current share price (Sept. 25, 2026 close). This is a research summary, not investment advice — verify against the original filings before acting.

Frequently asked questions

What does AbbVie do?

AbbVie develops and manufactures immunology, neuroscience, oncology, and aesthetics drugs — including Skyrizi, Rinvoq, and Botox — that patients take repeatedly for chronic conditions, selling through a small number of U.S. wholesalers.

How did AbbVie replace Humira's lost revenue?

After Humira faced U.S. biosimilar competition starting in 2023, follow-on drugs Skyrizi and Rinvoq grew fast enough that their combined revenue overtook Humira's peak by 2024, and total immunology revenue hit a record in 2025.

What is AbbVie's market cap?

As of this article's data (Sept. 25, 2026 close), AbbVie traded at $264.34 per share, for a market cap of roughly $468.1 billion.